More Troubles For Merck, AZ, Lilly, Takeda DPP-4s
This article was originally published in Scrip
Executive Summary
The FDA on Aug. 28 warned health care providers and patients about new concerns over severe and disabling joint pain linked to dipeptidyl peptidase-4 (DPP-4) inhibitors, such as Merck's Januvia (sitagliptin), AstraZeneca's Onglyza (saxagliptin), Lilly's and Boheringer Ingelheim's Tradjenta (linagliptin) and Takeda's Nesina (alogliptin) and their related products.